

## Third Dose COVID-19 Vaccine Referral Form

Clients must present this form **completed and signed by their physician or nurse practitioner** when attending their vaccine appointment. This form must indicate the client has completed a two-dose vaccine series and meets one or more of the criteria listed below.

Pharmacists and community physicians offering COVID-19 vaccination may also accept the referral for third doses. For information on where to get vaccinated in Halton, visit [halton.ca/COVIDvaccines](https://halton.ca/COVIDvaccines).

### Client Information

Last Name	First Name	Date of Birth	Health Card Number
COVID-19 Vaccine Information			
1 <sup>st</sup> dose vaccine name:		2 <sup>nd</sup> dose vaccine name:	
Date administered:		Date administered:	

### Physician/Nurse Practitioner Information

Patient Eligibility for a 3 <sup>rd</sup> Dose of COVID-19 Vaccine		
<p>Please indicate the relevant sub-category for 3<sup>rd</sup> dose eligibility:</p> <p><b>Note: Patient's must meet one or more of the criteria below, additional reasons for referral will not be accepted.</b></p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Recipient of a Solid Organ Transplant and taking immunosuppressive therapy.</li> <li><input type="checkbox"/> Recipient of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy).</li> <li><input type="checkbox"/> Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome).</li> <li><input type="checkbox"/> Individuals with stage 3 or advanced untreated HIV infection and those with acquired immunodeficiency syndrome.</li> <li><input type="checkbox"/> Individuals receiving active treatment<sup>1</sup> for solid tumour or malignant hematologic disorders.</li> <li><input type="checkbox"/> Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22 – including those who have completed treatment within 12 months), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive.</li> </ul> <p><sup>1</sup>Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g. solely hormonal therapy or radiation therapy). This includes patients who have completed treatment within 3 months.</p>		
Treatment Considerations for Timing of 3 <sup>rd</sup> Dose Interval		
<p>Please indicate any treatment considerations that may affect the timing for the 3<sup>rd</sup> dose interval:</p> <p>Note: The provincial recommended interval for 3<sup>rd</sup> doses is a minimum of 8 weeks (2 months). NACI recommends a minimum interval of 28 days between COVID-19 vaccine doses. However, a longer interval between doses is likely to result in a better immune response. To optimize the immune response and minimize delays in the management of underlying conditions, <b>if there are any treatment considerations, the treating physician must indicate the exact timing for the third dose.</b> The recommended interval should consider risk factors for exposure and risk of severe disease from COVID-19 infection.</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> No treatment considerations, client may receive 3<sup>rd</sup> dose in accordance with <a href="#">provincial guidance</a></li> <li><input type="checkbox"/> Yes, treatment must be considered</li> </ul> <p>Please specify 3<sup>rd</sup> dose interval recommendation: _____</p>		
Physician/Nurse Practitioner Name	Phone Number	Date
<input type="checkbox"/> I have provided counselling on the risks, benefits, and timing of a 3 <sup>rd</sup> dose of COVID-19 vaccine in accordance with <a href="#">provincial guidance</a> .		
Physician/Nurse Practitioner Signature		